Abstract Number: L12 • ACR Convergence 2023
Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis
Background/Purpose: TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis (PsO). TAK-279 is…Abstract Number: 0352 • ACR Convergence 2023
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…Abstract Number: 0495 • ACR Convergence 2023
Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
Background/Purpose: EISER is a cross-sectional, multicenter, observational, SER-GETECCU cooperative study involving 13 Spanish hospitals whose main objective was to estimate the prevalence of undiagnosed Inflammatory…Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…Abstract Number: 1044 • ACR Convergence 2023
Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts
Background/Purpose: Psoriatic arthritis (PsA) can manifest with different musculoskeletal (MSK) features. Ultrasound (US) optimizes the assessment of the different MSK features in PsA. However, there…Abstract Number: 1418 • ACR Convergence 2023
Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines involved in plaque psoriasis (PsO) and PsA pathophysiology. Deucravacitinib is a first-in-class, oral, selective, allosteric…Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…Abstract Number: 1688 • ACR Convergence 2023
Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
Background/Purpose: IL-17 inhibition demonstrates efficacy in multiple disease domains in psoriatic arthritis. Izokibep is a unique IL-17A inhibitor with high IL-17A binding affinity (KD= 0.3…Abstract Number: 2077 • ACR Convergence 2023
A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…Abstract Number: 2240 • ACR Convergence 2023
Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
Background/Purpose: The treatment paradigm for psoriatic arthritis (PsA) has changed over the last two decades, with increasing numbers of therapy options that target a variety…Abstract Number: 2438 • ACR Convergence 2023
Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function
Background/Purpose: Synovial fibroblasts (FLS) are key contributors to joint inflammation and damage in patients with Rheumatoid (RA) and Psoriatic Arthritis (PsA). Recent studies have identified…Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…Abstract Number: 0496 • ACR Convergence 2023
Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis
Background/Purpose: The atherogenic index of plasma (AIP) is a predictor of atherosclerosis and coronary heart disease. In patients with systemic lupus erythematosus and rheumatoid arthritis,…Abstract Number: 0541 • ACR Convergence 2023
Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study
Background/Purpose: Data regarding the adoption of the treat-to-target (T2T) approach aiming at inactive disease (ID), or low disease activity (LDA) in axial (axSpA) and peripheral…Abstract Number: 1051 • ACR Convergence 2023
Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis
Background/Purpose: Ultrasonography (US) has experienced a rapid evolution in rheumatology. Despite many advantages being shown repeatedly, several barriers persist and stand in the way of…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 81
- Next Page »